Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

Infection and Immunity

Volumn 69, Issue 7, 2001, Pages 4545-4553

  Fries, L F ^a   Montemarano, A D ^a   Mallett, C P ^a   Taylor, D N ^a   Hale, T L ^a   Lowell, G H ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SHIGELLA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; SHIGELLA FLEXNERI;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY-PRODUCING CELLS; CONSUMER PRODUCT SAFETY; FECES; FEMALE; HEALTH STATUS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; SHIGELLA FLEXNERI; SHIGELLA VACCINES;

EID: 0034967546     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.7.4545-4553.2001     Document Type: Article

References (36)

1. Adverse events following vaccine or placebo rejection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991
2. Doubleblind, vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults
3. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population
4. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide
5. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis
6. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination
7. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
8. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells
9. Failure of parenteral vaccines to protect monkeys against experimental shigellosis
10. The effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei
11. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile toxin) B subunits supplemented with a trace amount of the holotoxin on the brain
12. Shigella vaccines
13. Studies in volunteers to evaluate candidate Shigella vaccines: Further experience with bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease
14. Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment
15. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine
16. Active immunity is seen as a reduction in the cell response to oral live vaccine
17. Comparison of the human immune response to live oral, killed oral, or killed parenteral Salmonella typhi Ty21a vaccines
18. Safety, immunogenicity and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen
19. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2
20. Hyperendemic shigellosis in the United States: A review of surveillance data for 1967-1988
21. Proteosomes for improved nasal, oral or injectable vaccines
22. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: Immunogenicity and efficacy against lethal SEB intoxication in mice
23. Proteosomes, emulsomes and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal and lung IgA and IgG
24. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection
25. The common mucosal immune system and current strategies for induction of immune response in external secretions
26. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes
27. Mucosal immunoprophylaxis: An introductory overview
28. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models
29. Oral vaccines for Shigella
30. Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion
31. Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh
32. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge
33. Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA
34. Immunoglobulin A. Strategic defence initiative at the mucosal surface
35. Bacterial lipopolysaccharides: Extraction with phenol-water and further applications of the procedure
36. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate